Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease…

Posted: June 22, 2022 at 2:43 am

-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned

Read the original:
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease...

Related Posts